Robert Z. Orlowski, MD, PhD
MD Anderson Cancer Center
Interview Date: January 8, 2019
There is a tremendous amount of progress being made in multiple myeloma. It was stunning to see the significant work being done in the field of myeloma at the recent American Society of Hematology meeting in San Diego. We are very fortunate as myeloma patients to have the breadth and depth of new developments for our disease by a wide variety of companies.
Myeloma expert Dr. Robert Orlowski of the MD Anderson Cancer Center shares his top 18 abstracts of 2018 and covers every stage of disease from early conditions like smoldering myeloma, treatments for newly diagnosed patients and options and clinical trials being run for relapsed patients.
Learn why myeloma is being treated earlier and how researchers are working to prevent progression to active myeloma. Hear more about the status of immunotherapies - like BiTEs, CAR T treatment, antibody drug conjugates and others. Dr. Orlowski shares an incredible summary of topics to consider at each phase of disease in a clear and concise way. There is much to be learned in this valuable show.
Thanks to our episode sponsor
Robert Z. Orlowski, M.D., Ph.D., is Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, where he is board-certified in medical oncology. Dr. Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University and his medical degree from the Yale University School of Medicine. He completed his internship and residency in Internal Medicine at Barnes Hospital at the Washington University in St. Louis School of Medicine. After his fellowships in Hematology and Medical Oncology at John Hopkins Sidney Kimmel Comprehensive Cancer Center, he joined the faculty at University of North Carolina in Chapel Hill. Following that, Dr. Orlowski accepted a position at The University of Texas MD Anderson Cancer Center in 2007 to lead the Myeloma Section in the Department of Lymphoma/Myeloma. His research interests include pathobiology of, novel therapeutic targets and mechanisms of drug resistance in myeloma which are documented in hundreds of scientific articles, book chapters, and presentations at conferences. Dr. Orlowski is an investigator on numerous clinical trials, and appointed Myeloma Committee Chair for SWOG.
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
+1 800 709 1113